钙调磷酸酶抑制剂（CNI）包括口服环孢素A和他克莫司，是强效免疫抑制剂，在中国广泛用于治疗风湿病和免疫性疾病。 CNI通过抑制细胞内钙调神经磷酸酶的活化，减少IL的释放，选择性抑制T淋巴细胞的活化和增殖以及细胞因子[如肿瘤坏死因子-α、白细胞介素(IL)-6和IL-17]的转录-2。为规范CNI在风湿免疫疾病领域的使用，国家皮肤免疫疾病临床医学研究中心（北京协和医院）会同中国风湿免疫医师协会制定本共识。 、中国研究型医院协会、风湿免疫学专业委员会、中国康复医学会。 2011 年牛津循证医学中心的证据水平用于评估证据的质量和建议的强度，并遵循 RIGHT（医疗保健实践指南的报告项目）清单来报告共识。该共识针对中国临床医生面临的九项临床挑战提出了建议。本共识的主要目的是为中国临床医生提供科学、细致的CNI指导，提高以患者为中心的医疗服务质量。

Calcineurin inhibitors (CNI), including oral cyclosporin A and tacrolimus, are intensive immunosuppressants that are extensively used in the treatment of rheumatic and immunologic diseases in China. CNI selectively inhibit the activation and proliferation of T lymphocytes and the transcription of cytokines [such as tumor necrosis factor-α, interleukin (IL)-6, and IL-17] through inhibiting the activation of calcineurin in cells and reducing the release of IL-2. To standardize the use of CNI in the field of rheumatic and immunologic diseases, this consensus statement was developed by the National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), in conjunction with the Chinese Association of Rheumatology and Immunology Physicians, the Chinese Research Hospital Association, the Rheumatology and Immunology Professional Committee, and the Chinese Association of Rehabilitation Medicine. The 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence was used to rate the quality of the evidence and the strength of the recommendations, and the RIGHT (Reporting Items for practice Guidelines in HealThcare) checklist was followed to report the consensus. The consensus offers recommendations addressing nine clinical challenges to Chinese clinicians. The primary objective of this consensus is to deliver scientific and detailed guidance on CNI for Chinese clinicians, and to improve the quality of patient-centered medical services.